CA2814840C - Sustained-release formulation for injection - Google Patents

Sustained-release formulation for injection Download PDF

Info

Publication number
CA2814840C
CA2814840C CA2814840A CA2814840A CA2814840C CA 2814840 C CA2814840 C CA 2814840C CA 2814840 A CA2814840 A CA 2814840A CA 2814840 A CA2814840 A CA 2814840A CA 2814840 C CA2814840 C CA 2814840C
Authority
CA
Canada
Prior art keywords
formulation
solution
crystal
active ingredient
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2814840A
Other languages
English (en)
French (fr)
Other versions
CA2814840A1 (en
Inventor
Takashi Nakagawa
Norimasa Koseki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CA2814840A1 publication Critical patent/CA2814840A1/en
Application granted granted Critical
Publication of CA2814840C publication Critical patent/CA2814840C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2814840A 2010-10-18 2011-10-18 Sustained-release formulation for injection Expired - Fee Related CA2814840C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39406910P 2010-10-18 2010-10-18
US61/394,069 2010-10-18
PCT/JP2011/074375 WO2012053654A1 (en) 2010-10-18 2011-10-18 Sustained-release formulation for injection

Publications (2)

Publication Number Publication Date
CA2814840A1 CA2814840A1 (en) 2012-04-26
CA2814840C true CA2814840C (en) 2018-08-28

Family

ID=45933169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2814840A Expired - Fee Related CA2814840C (en) 2010-10-18 2011-10-18 Sustained-release formulation for injection

Country Status (7)

Country Link
US (3) US9469630B2 (https=)
EP (1) EP2629775A4 (https=)
JP (4) JP5893616B2 (https=)
KR (1) KR101936968B1 (https=)
CN (3) CN107625728A (https=)
CA (1) CA2814840C (https=)
WO (1) WO2012053654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014084921A1 (en) * 2012-11-27 2014-06-05 Rose Stuart Pharmaceutical manufacturing method and compositions
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
KR101792414B1 (ko) * 2016-05-19 2017-11-01 삼성전기주식회사 박막 커패시터 및 그 제조방법
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
JPWO2018043613A1 (ja) * 2016-08-31 2019-06-24 大日本住友製薬株式会社 水性懸濁型製剤
US10252229B2 (en) * 2017-06-30 2019-04-09 Snowie LLC System comprising a pump attached to a tank casing for mixing a fluid
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
CN111989102A (zh) * 2018-02-28 2020-11-24 大日本住友制药株式会社 水性混悬液型药物制剂
JP7214103B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JPWO2020179925A1 (https=) * 2019-03-07 2020-09-10
CN110478131B (zh) * 2019-08-05 2022-01-11 思必康（厦门）新材料有限公司 一种pH响应变色的纱布及其制备方法和该纱布的应用
US11041740B1 (en) 2019-12-20 2021-06-22 EmpNia Inc. Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
WO2022034489A1 (en) * 2020-08-11 2022-02-17 Auxilla Pharmaceuticals And Research Llp A non-aqueous suspension of anticancer agent
CA3210098A1 (en) 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN116848108A (zh) 2021-03-31 2023-10-03 四川科伦药物研究院有限公司 一种鲁拉西酮可注射混悬液及其制备方法
CN120078778A (zh) * 2024-09-25 2025-06-03 山东百诺医药股份有限公司 一种伏硫西汀酯药物组合物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6169084B1 (en) 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
FI105074B (fi) 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
HK1041199B (en) 1998-09-30 2005-03-18 Eli Lilly & Company 2-Methyl-thiophenone-benzodiazine formula
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
DE10218110A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
KR101085806B1 (ko) 2003-07-29 2011-11-22 다이닛본 스미토모 세이야꾸 가부시끼가이샤 이미드 화합물의 제조 방법
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
CN101106972A (zh) 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
RU2407529C2 (ru) 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
DK1884242T3 (da) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
US8283352B2 (en) * 2005-06-13 2012-10-09 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007106768A2 (en) 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
BRPI0820745A2 (pt) 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos

Also Published As

Publication number Publication date
US20190010149A1 (en) 2019-01-10
JP6173502B2 (ja) 2017-08-02
KR101936968B1 (ko) 2019-01-09
CN103249416B (zh) 2019-06-04
JP5893616B2 (ja) 2016-03-23
EP2629775A1 (en) 2013-08-28
JP6410889B2 (ja) 2018-10-24
WO2012053654A1 (en) 2012-04-26
JP2017206543A (ja) 2017-11-24
JP2013543481A (ja) 2013-12-05
JP2016128503A (ja) 2016-07-14
CN103249416A (zh) 2013-08-14
CN107595771A (zh) 2018-01-19
EP2629775A4 (en) 2014-06-11
US20120091022A1 (en) 2012-04-19
CA2814840A1 (en) 2012-04-26
JP2019006822A (ja) 2019-01-17
US9469630B2 (en) 2016-10-18
CN107625728A (zh) 2018-01-26
US20160158228A1 (en) 2016-06-09
KR20130139978A (ko) 2013-12-23

Similar Documents

Publication Publication Date Title
CA2814840C (en) Sustained-release formulation for injection
RU2750163C2 (ru) Таксановые частицы и их применение
US9096547B2 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
JP2013543481A5 (https=)
US9050265B2 (en) Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
NO332937B1 (no) Frysetorket pantoprazol-preparat og fremgangs-mate ved fremstilling av det samme samt pantoprazol-injeksjonspreparat» slik at den omfatter en omtale av de ulike aspektene ved oppfinnelsen
KR20070090070A (ko) 목적하는 평균 입자크기의 멸균 아리피프라졸을 제조하는방법
CN103429224A (zh) 用于治疗口腔疾病的包含瑞巴派特的药物组合物
CN102225063B (zh) 一种供注射用的泮托拉唑钠组合物
CN102178604A (zh) 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
WO2021049963A1 (en) Pharmaceutical composition of bimatoprost and timolol
JP2025024083A (ja) 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液
US20240197623A1 (en) Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
CN111973613B (zh) 一种复方大观霉素粉针及其制备方法
CN100346782C (zh) 一种含氨基酸的维生素c组合物
CN1689564A (zh) 一种含维生素c钠的维生素c组合物
RU2209086C1 (ru) Способ получения диуретического средства
CN106518854A (zh) 一种盐酸维拉佐酮晶型ⅳ的制备方法
ITMI20130426A1 (it) S-adenosilmetionina sterile ad alto contenuto di isomero attivo per soluzioni iniettabili e procedimento per ottenerla
WO2011016435A1 (ja) ポリ乳酸粒子含有凍結乾燥組成物の製造方法
CN1631357A (zh) 一种反向温敏型注射式原位成型植入制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160901

MKLA Lapsed

Effective date: 20201019